News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News August 19, 2026
Gibson Dunn Represented SCIH Salt Holdings in $1.6 Billion Notes Offering, $3.2 Billion Term Loan B Facility, and $550 Million Revolving Credit Facility
Gibson Dunn represented SCIH Salt Holdings Inc., the largest producer of salt in the Americas and the parent of the Morton Salt, Windsor Salt, and LOBOS businesses, in a Rule 144A and Regulation S offering of $1.1 billion in aggregate principal amount of 6.625% Senior First Lien Notes due 2031 and $500 million in aggregate principal amount of 8.000% Senior Notes due 2032.
Firm News April 23, 2026
Gibson Dunn Advised Catchment Capital on Isolatek Acquisition
Gibson Dunn advised Catchment Capital, a private equity firm focused on transforming middle market industrial businesses, on its acquisition of Isolatek, a leading manufacturer and supplier of passive fireproofing technologies, from SK Capital.
Firm News October 28, 2025
Gibson Dunn Advised BVP Forge on Investment in Strategic Combination of Sunwave Health and Lightning Step
Gibson Dunn advised BVP Forge on its investment in the strategic combination of Sunwave Health and Lightning Step to form a unified technology platform, purpose-built for behavioral health providers nationwide
Firm News August 15, 2025
Gibson Dunn Represents RTW Investments in Acquisition of Synthetic Royalty Interest in Anaphylm™
Gibson Dunn is representing RTW in its acquisition from Aquestive Therapeutics of a synthetic royalty interest in Anaphylm™ (epinephrine) Sublingual Film, and in its acquisition of Aquestive common stock as the lead investor in the company’s $85 million underwritten offering
Firm News July 3, 2025
Gibson Dunn Represented HealthCare Royalty and Blue Owl Capital in Acquisition of BridgeBio Pharma’s Royalty Interest in Bayer’s BEYONTTRA®
Gibson Dunn advised HealthCare Royalty and Blue Owl Capital on their acquisition from BridgeBio Pharma of its royalty interest in Bayer’s BEYONTTRA® for $300 million.